CombixBio

PARTNERSHIP BRIEF

Turn a development question into a focused study.

AI-guided combination discovery, experimental biology and delivery matching for pharma, biotech and formulation teams.



THREE CONNECTED AI ENGINES

CombixProfilers

Cell-model-specific drug-pair discovery.

CombixOncoInfer

Research hypotheses for oncology response.

CombixVector

Candidate-to-modality and modality-to-candidate matching.

Four starting points for collaboration

STARTING POINT	DECISION TO INVESTIGATE
New combination programs	Which complementary mechanisms warrant a focused test?
Shelved asset rescue	Could a new partner, setting or delivery approach address the original limitation?
Pipeline expansion	Which combinations or disease contexts merit further investigation?
Delivery matching	Which candidates fit liposomes, PLGA or other platforms - and vice versa?

PUBLISHED FOUNDATION

Mechanism-informed AI and oxygenated 3D screening identified berberine + enzalutamide synergy across four prostate cancer models.
Advanced Science (2026) | doi:10.1002/advs.78186 | Published in vitro evidence.

Bring an asset or disease setting, a limitation, and your next decision.

Share nonconfidential information only. Studies, responsibilities and deliverables are agreed individually.

info@combixbio.com

combixbio.com/partnerships

Research predictions require experimental validation; in vitro findings do not establish clinical efficacy.